Company news

Ascentage Pharma Group International news in 2025

Ascentage Pharma Group International's news releases, calls and decks from 2025, newest first.

View company

Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

December 7, 2025

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

December 7, 2025

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

December 7, 2025

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

December 6, 2025

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

December 6, 2025

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

December 3, 2025

Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025

December 1, 2025

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy

November 23, 2025

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025

November 19, 2025

Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

November 3, 2025

Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025

November 3, 2025

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025

October 28, 2025

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025

October 7, 2025

Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025

August 25, 2025

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

August 20, 2025

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

August 17, 2025

Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025

August 7, 2025

Ascentage Pharma to Participate in Evercore China Biotech Summit

August 1, 2025

Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025

July 23, 2025

Ascentage Pharma Announces Pricing of Top-Up Placement

July 14, 2025

Ascentage Pharma Announces Proposed Top-Up Placement

July 14, 2025

Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL

July 10, 2025

Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance

July 7, 2025

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

June 15, 2025

Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress

June 9, 2025

Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors

June 2, 2025

Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report

June 2, 2025

Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025

May 22, 2025

Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax

April 28, 2025

Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin

April 23, 2025

Calls in 2025

Decks in 2025